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Introduction  
 1 
INTRODUCTION 
 
The induction of labour in women with a live fetus at term remains 
a major challenge in modern obstetrics. Some centuries ago fetal death 
was the only indication for labour induction.  Nowadays the rate of labour 
induction varies in different centers and is approximately more than 
20%1. Despite a large body of literature on the subject, the optimal agent 
for this purpose has yet to be established. 
Induction of labour includes natural, mechanical, surgical and 
pharmacological methods. Preference for particular method is not yet 
established completely and it depends on particular institute protocol. 
Pharmacological methods include oxytocin, misoprostol, mifepristone, 
dinoprostone etc. In the presence of unfavorable cervix induction is 
associated with increased risk of failed induction and caesarean section2. 
Hence to increase the likelihood of successful induction and decrease 
caesarean delivery risk cervical ripening is needed .The use of 
prostaglandin preparations with or without oxytocin infusion was widely 
recognised and accepted as a standard method for cervical ripening and 
labour induction3.  However, natural prostaglandins are inconvenient to 
use, expensive and difficult to store, as they require refrigeration4.  
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Misoprostol is a prostaglandin E1 analogue marketed since1988, as 
a gastric cytoprotective agent. It was first used to induce labour with a 
live fetus in 1991 and has gained wide spread acceptance for labour 
induction after several studies. Several routes of administration of 
misoprostol have been studied which had included oral, vaginal, rectal, 
buccal, and sublingual.5 
Vaginal administration of misoprostol is a common route of 
practice for labour induction but it incurs a greater risk of undesirable 
adverse effects, such as uterine hyperstimulation syndrome, as well as 
having the inconvenience of vaginal administration6. To avoid this 
undesirable effect and inconvenience of vaginal administration, studies 
were conducted on oral route of misoprostol.  Many clinical studies had 
found that vaginal administration was more effective than oral 
administration as systemic bioavailability after vaginal misoprostol was 
three times greater than the oral misoprostol.7  To overcome the 
hyperstimulation syndrome and inconvenience in vaginal administration 
of vaginal misoprostol, lesser bioavailability in oral misoprostol, an 
alternative method was sought. Theoretically sublingual method of 
administration may be an alternative method as it combines the higher 
efficacy of vaginal route by avoiding gastrointestinal and hepatic 
metabolism and the lower hyperstimulation rates by avoiding a direct 
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effect on the cervix. Similar to the oral route, sublingual misoprostol has 
additional advantages, which include its easier administration, greater 
freedom of position after insertion and avoidance of repeated vaginal 
examinations8. 
The initial dose of vaginal misoprostol used was 50 micrograms 
every 2 hours up to a maximum total dose of 600 micrograms, resulting 
in vaginal delivery in 73% of cases and hyperstimulation syndrome in 
3.6% of women.9,10  Since then, lower doses have been proposed for the 
induction of labour in an attempt to reduce adverse effects6,11. After 
several studies, WHO and FIGO had recommended vaginal misoprostol 
dosage of 25 microgram every 4 hourly for maximum of 6 doses12. The 
utilization of sublingual misoprostol for labour induction with viable 
pregnancy had not been reported in the literature prior to 20018. 
Pharmacokinetics study of different route of misoprostol had showed that 
sublingual route had greater bioavailability than vaginal route5. 
The objectives of this study were to determine the efficacy and 
safety of 25 microgram of sublingual misoprostol compared with 25 
microgram of vaginal misoprostol for the induction of labour, in women 
with a live, term fetus and an unripe cervix. 
 
 
  
 
 
 
 
 
Aim of study
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AIM OF STUDY 
 
To compare the efficacy and safety of 25 microgram of sublingual 
misoprostol with 25 microgram of vaginal misoprostol administered at          
4-hour intervals for maximum of 6 doses for labour induction in term 
pregnancy with an unripe cervix. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Review of  
Literature 
 5 
REVIEW OF LITERATURE 
INDUCTION OF LABOUR 
Definition 
 Stimulation of uterine contraction before the spontaneous onset of 
labour, anytime after fetal viability, with or without rupture membranes, 
for the purpose of achieving vaginal delivery.13,14 
Patient prerequisite for induction 
Ø Assessment of maternal parameters 
o Confirm the indication for induction 
o Review for contraindication to labour and/or vaginal 
delivery  
o Assess the shape and adequacy of bony pelvis 
o Assess the cervical status by Bishop score 
o Review risk and benefit of induction of labour with patient 
and the family 
Ø Assessment of fetal parameters 
o Confirm the gestational age 
o Estimate fetal weight 
o Determine fetal position 
o Determine fetal well being 
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Indication15 
Ø Obstetric indication: 
o Post term pregnancy 
o Preeclampsia, eclampsia  
o Previous unexplained IUD 
o Fetal compromise (eg, severe fetal growth restriction, 
isoimmunization) 
o Premature rupture of membranes 
o Malformed fetus 
o Severe  hydraminos 
o Unexplained oligo hydraminos 
o Gestational diabetes mellitus 
o Abruptio placentae 
o Chorioamnionitis 
o Fetal demise 
Ø Maternal medical conditions  
o diabetes mellitus 
o chronic  renal disease,  
o chronic pulmonary disease  
o chronic hypertension 
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Contraindication16 
Ø Absolute 
o Active genital herpes infection 
o Serious chronic medical condition 
o Pelvic Structural abnormality 
o Cephalopelvic disproportion major degree 
o Abnormal fetal lie [transverse lie, oblique lie] 
o Umbilical cord prolapse   
o Placenta previa of major degree and vasa previa 
o Previous classical Cesarean section or other transfundal 
uterine surgery 
o Contraindication specific to the inducing drug used. 
Ø Relative 
o Invasive cervical cancer 
o Uterine overdistension [multiple pregnancy, poly 
hydraminos] 
o Malpresentation [breech] 
o Fetal macrosomia 
o Low lying placenta 
o Unexplained vaginal bleeding 
o Cord presentation 
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o Myomectomy involving uterine cavity 
o Abnormal fetal heart pattern 
Bishop Scoring System17 
 Factor 
Score Dilation (cm) 
Effacement 
(%) Station
* Cervical Consistency 
Position of 
Cervix 
0 Closed 0-30 -3 Firm Posterior 
1 1-2 40-50 -2 Medium Midposition 
2 3-4 60-70 -1,0 Soft Anterior 
3 5-6 80 +1,+2 -- -- 
*Station reflects - 3 to +3 scale. 
 
Methods of Labor Induction18 
I-Non pharmacologic methods 
· Natural method 
o Relaxation techniques 
o Sexual intercourse 
o Nipple stimulation 
o Hot Bath / Castor oil / Enemas 
o Foods 
o Cumin Tea 
o Several herbs 
o Acupressure 
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· Mechanical methods 
o Osmotic dilators 
§  Laminaria 
§ dilapan 
o Balloon devices 
§ Foleys 
§ Bougie 
II- Surgical methods 
· stripping the membranes 
· Amniotomy 
III- Pharmacological methods 
· Oxytocin 
· Prostaglandin 
o Misoprostol [ E1] 
o Dinoprostone [E2]  
· Mifepristone                 
The addition of oxytocin along with the use of the Foley catheter 
does not appear to shorten the time of delivery in a randomized controlled 
trial19. Studies examining extraamniotic saline infused through the Foley 
catheter compared with use of the Foley catheter with concurrent 
oxytocin administration report conflicting results on the time from  
induction to delivery20. Differences in methodology could explain the 
opposing findings.   The  Foley  catheter  was  a  reasonable and effective  
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alternative for cervical ripening and inducing labor. Intracervical or 
intravaginal PGE2 commonly was used and was superior to placebo or no 
therapy in promoting cervical ripening21. Several prospective randomized 
clinical trials and two meta-analyses have demonstrated that PGE1 
(misoprostol) was an effective method for cervical ripening22. 
Misoprostol administered intravaginally had been reported to be either 
superior to or as efficacious as dinoprostone gel23. Vaginal misoprostol 
had been associated with less use of epidural analgesia, more vaginal 
deliveries within 24 hours, and more uterine tachysystole with or without 
FHR changes compared with dinoprostone and oxytocin. It was difficult, 
however, to compare the results of studies on misoprostol because of 
differences in endpoints, including Bishop Score, duration of labor, total 
oxytocin use, successful induction, and cesarean delivery rate24. 
Pharmacologic methods for cervical ripening did not decrease the 
likelihood of cesarean delivery. 
In December 2000, the American College of Obstetricians and 
Gynecologists reaffirmed its recommendation for use of the drug because 
of proven safety and efficacy25. Misoprostol tablets placed into the vagina  
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were either superior to or equivalent in efficacy when compared with 
intracervical prostaglandin E2 gel26. Misoprostol use may decrease the 
need for oxytocin, achieve higher rates of vaginal delivery within 24 
hours of induction, and reduce induction-to-delivery intervals. 
Misoprostol costs less than compared with dinoprostone gel and it does 
not need refrigeration. 
Misoprostol - Clinical Pharmacology  
Misoprostol is a synthetic prostaglandin E1 analog. Misoprostol 
contains approximately equal amounts of the two diastereomers presented 
below with their enantiomers indicated by (±): 
 
Pharmacokinetics27 
Misoprostol is a water soluble compound.28  Misoprostol is 
extensively absorbed, and undergoes rapid de-esterification to its free 
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acid (Misoprostolic acid), which is responsible for its clinical activity 
and, unlike the parent compound, is detectable in plasma. The alpha side 
chain undergoes beta oxidation and the beta side chain undergoes omega 
oxidation followed by reduction of the ketone to give prostaglandin F 
analogs. In normal volunteers, Misoprostol is rapidly absorbed after oral 
administration with a Tmax of Misoprostol acid of 12 ± 3 minutes and a 
terminal half-life of 20–40 minutes. 
Route5 Onset  of    action5 Duration of action5 
Oral * 8 min ~ 2 h 
Sublingual 11 min ~ 3 h 
Vaginal 20 min ~ 4 h 
Rectal 100 min ~ 4 h 
 
Pharmacodynamics27 
Misoprostol has both antisecretory (inhibiting gastric acid 
secretion) and (in animals) mucosal protective properties. NSAIDs inhibit 
prostaglandin synthesis, and a deficiency of prostaglandins within the 
gastric mucosa may lead to diminishing bicarbonate and mucus secretion 
and may contribute to the mucosal damage caused by these agents. 
Misoprostol can increase bicarbonate and mucus production, but in man 
this has been shown at doses 200 mcg and above that are also 
antisecretory.  
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Uterine Effects 
Misoprostol has been shown to produce uterine contractions that 
may endanger pregnancy  
 
Indications and Usage for Misoprostol 
1. Misoprostol is indicated for the prevention of gastric ulcer 
associated with the use of nonsteroidal anti-inflammatory drugs 
(NSAIDs), including aspirin, in patients at high risk of complications 
from gastric ulcer, such as the elderly, and in patients with concomitant 
disease or patients at high risk of developing gastric ulceration, such as 
those with a history of ulcer.29 
2. The efficacy and tolerability of mifepristone in combo with 
misoprostol for termination of early pregnancy (up to 49 days of 
amenorrhea) are established.30 
3.  Misoprostol, in very low doses, was a remarkably efficient and 
safe method for induction of labor.31 
 
Pregnancy: Category X32 
Teratogenic effects  
  Several reports in the literature associate the use of Misoprostol 
during the first trimester of pregnancy with skull defects, cranial nerve 
palsies, facial malformations, and limb defects.33 
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Nonteratogenic effects 
Misoprostol may endanger pregnancy (may cause abortion) and 
thereby cause harm to the fetus when administered to a pregnant 
woman.34 
 
Labor and delivery 
Misoprostol can induce or augment uterine contractions. Vaginal 
administration of Misoprostol, outside of its approved indication, has 
been used as a cervical ripening agent, for the induction of labor and for 
treatment of serious postpartum hemorrhage in the presence of uterine 
atony35. A major adverse effect of the obstetrical use of Misoprostol is 
hyperstimulation of the uterus which may progress to uterine tetany with 
marked impairment of uteroplacental blood flow, uterine rupture 
(requiring surgical repair, hysterectomy, and/or salpingo-oophorectomy), 
or amniotic fluid embolism. Pelvic pain, retained placenta, severe genital 
bleeding, shock, fetal bradycardia, and fetal and maternal death have been 
reported.27 
There may be an increased risk of uterine tachysystole, uterine 
rupture, meconium passage, meconium staining of amniotic fluid, and 
cesarean delivery36 due to uterine hyperstimulation with the use of higher 
doses of misoprostol.  The risk of uterine rupture increases with 
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advancing gestational ages and with prior uterine surgery, including 
cesarean delivery.37  Grand multiparity also appears to be a risk factor for 
uterine rupture. 
The effect of Misoprostol on the later growth, development, and 
functional maturation of the child when Misoprostol is used for cervical 
ripening or induction of labor had not been established yet. Information 
on misoprostol’s effect on the need for forceps delivery or other 
intervention is unknown. 
Nursing mothers 
Caution should be exercised when Misoprostol is administered to a 
nursing woman.27 
Pediatric Use 
Safety and effectiveness of Misoprostol in pediatric patients have 
not been established.27 
Adverse Reactions 
1. Diarrhea  
2. Abdominal pain. 
3. Nausea  
4. Flatulence  
5. Headache  
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6. Dyspepsia  
7. Vomiting  
8. Constipation  
9. Spotting 
10. Cramps  
11. Hypermenorrhea  
12. Menstrual disorder  
13. Dysmenorrhea 
 
Misoprostol Dosage and Administration38 
Indication Dosage 
Nsaid’s ulcer prophylaxis 200 mcgx4 times 
Induced abortion  (0-12 weeks) 800mcg vaginally 12-hrly x3 
Missed abortion    (0-12 weeks) 800mcg vaginal 3-hrly or sublingual 600mcg 3-hourly 
Incomplete abortion (0-12weeks) 600mcg orally single dose 
Induced abortion   (13-22 weeks) 400mcg vaginally 3-hrly x5 
Intrauterine fetal death 
13-17 wks: 200mcg pv 6-hrly. 
18-26 wks: 100mcg pv 6-hrly. 
27+ wks: 25-50mcg pv 4-hrly 
Induction of labour 25mcg vaginally 4-hrly or 50 mcg orally 4-hrly or 20mcg oral solution 2-hrly 
PPH prophylaxis 600mcg orally or sublingually stat 
PPH treatment 600mcg orally or sublingually stat 
Cervical ripening 400mcg vaginally 3h before procedure 
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Overdosage 
The toxic dose of Misoprostol in humans has not been determined. 
Cumulative total daily doses of 1600 mcg have been tolerated, with only 
symptoms of gastrointestinal discomfort being reported38. 
 
Contraindications 
Misoprostol should not be taken by pregnant women to reduce the 
risk of ulcers induced by non-steroidal anti-inflammatory drugs 
(NSAIDs).  Misoprostol should not be taken by anyone with a history of 
allergy to prostaglandins. 
 
Precautions 
Caution should be employed when administering Misoprostol to 
patients with pre-existing cardiovascular disease. 
A. Aronsson et al40 had studied the effect of misoprostol 
administered by different routes on pregnant uterine contractility. They 
had observed an increase in uterine tonus, which occurred after a 
significantly shorter time following oral (7.8 min) and sublingual 
(10.7±11.5 min) than after vaginal (19.4 min) treatment. The time to 
maximum tonus elevation was also significantly shorter (39.5, 47.1±51.7 
and 62.2 min for the three groups respectively). Regular uterine 
contractions developed in all subjects following sublingual and vaginal 
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administration but not after oral administration. The increase in uterine 
activity measured in Montevideo Units was significantly higher after 2 h 
and thereafter for sublingual and vaginal treatment than for oral 
misoprostol. Based on recording of uterine activity, sublingual 
misoprostol acts as rapidly as oral treatment, while development of 
contractions was similar to that seen following vaginal administration. 
AH Nassar et al.8 had studied the patient satisfaction with two 
routes of misoprostol for term labour induction. Despite a similar 
proportion reporting the labour induction as more painful than expected 
in both groups, a significantly lower proportion mentioned that the pelvic 
examinations were very painful in the sublingual group (19.7 versus 
36.1%, relative risk [RR] 0.5, 95% CI 0.3–0.9).  Request for analgesia 
was similar in both groups. More women in the sublingual group thought 
that the labour experience was better than expected (RR 2.0, 95% CI  
1.2–3.3), had a positive attitude towards induction in subsequent 
pregnancies (RR 1.6, 95% CI 1.1–2.3) and preferred the same route in 
subsequent pregnancies (RR 3.1, 95% CI 2.2–4.5). Mean number of 
misoprostol doses, oxytocin augmentation, tachysystole and 
hyperstimulation, induction to vaginal delivery interval, vaginal delivery 
after a single dose, vaginal birth within 12 and 24 hours, and caesarean 
delivery rates were similar in both groups. They had concluded that 
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sublingual misoprostol (50 micrograms) is associated with a significantly 
higher patient satisfaction rate compared with a similar dose of vaginal 
misoprostol. Sublingual administration offers additional choice to 
women, in particular those wishing to avoid vaginal administration. 
A Bartusevicius et al.4 studied the efficacy and safety of 50 μg of 
sublingual misoprostol with 25 μg of vaginal misoprostol administered 
for labour induction at term. They found that the induction to vaginal 
delivery time was significantly shorter in the sublingual group (15.0 ± 3.7 
hours) compared with the vaginal group (16.7 ± 4.1 hours, P = 0.03). The 
incidence of tachysystole was more than three-fold higher in the 
sublingual than in the vaginal group (14 versus 4.3%; RR 3.3, 95% CI 
0.9–11.6), but this was not statistically significant. There were no 
significant differences in the incidence of hypertonus or hyperstimulation 
syndrome, mode of delivery, interventions for fetal distress or neonatal 
outcomes between the two groups 
Yvette Pernella Geels et al.41 had studied the complications and 
effectiveness of induction after vaginal and sublingual administration of 
misoprostol for labor induction in women with intra-uterine fetal death 
(IUFD). In the vaginal group 28.6% had one or more complications 
compared to 21.7% in the sublingual group. In the sublingual group three 
inductions did not lead to delivery within 48 hours (13%), compared to 
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four in the other group (19%).The mean induction to delivery time in the 
sublingual group was13 hours and17 hours in the vaginal group. They 
had concluded that both sublingual and vaginal misoprostol were safe and 
efficient for labor induction in women with IUFD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material & 
 Methods 
 21 
MATERIALS AND METHODS 
 
This study was conducted in ANNAL GANDHI MEMORIAL 
GOVERNMENT HOSPITAL, TIRUCHIRAPALLI, TAMILNADU in the 
Department of obstetrics and gynecology during the period of June 2009 – 
August 2010 after getting approval from ethical committee.   120 patients 
those for labour induction at term were included in this study.  60 patients 
were administered sublingual misoprostol and remaining 60 patients were 
administered vaginal misoprostol.  
 
Inclusion criteria 
·  Live singleton pregnancy at a gestational age of 37 completed 
weeks or more with a medical or obstetric indication for induction 
including gestational age ³ 41 weeks [PD], prelabour rupture of  
membrane [PROM], mild preeclampsia [MPE] and gestational 
diabetes mellitus [GDM] 
· Both nulliparous and multiparous women 
· A cephalic presentation 
· An unfavorable cervix (Bishop's score less than or equal to 6) 
· A reassuring fetal heart tracing. 
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Exclusion Criteria 
· Multiple gestation 
· Malpresentation (presentation other than cephalic) 
· Previous uterine surgery including cesarean surgery 
· Known contraindications to the use of prostaglandins (e.g. asthma) 
· Grandmultiparity (more than 5) 
· Need for immediate delivery 
· Chorioamnionitis or hyperthermia > 38ºC 
· Active vaginal bleeding 
· Ultrasonically estimated oligohydramnios, polyhydramnios, 
suspicion of fetal malformation, macrosomia or growth restriction. 
Women who fulfilled these criteria were included in this study. 
Randomization was done by computer prepared data. They had been 
divided into 2 groups. 
 
Group A: sublingual misoprostol [SLM] 
60 patients for labour induction were randomly allocated for 25 
microgram sublingual misoprostol administration every 4th hourly for 
maximum of 6 doses. 
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Group B: vaginal misoprostol [VM] 
60 patients for labour induction were randomly allocated for 25 
microgram vaginal misoprostol administration every 4th hourly for 
maximum of 6 doses. 
 
Method 
Each women was allocated to receive 25 microgram sublingual 
misoprostol every 4th hourly for maximum of 6 doses in group A and 25 
microgram vaginal misoprostol administration every 4th hourly for 
maximum of 6 doses. If  patient had atleast three regular contraction in 10 
minutes, enteres active phase of labour [regular uterine contraction and 
cervical dilatation greater than or equal to 3 cms] and cervix favourable 
for amniotomy [Bishop score greater than or equal to 8], then subsequent 
dose of misoprostol was withheld. As soon as fetal head engagement and 
cervical dilation permitted, amniotomy was performed, followed by 
oxytocin augmentation if the frequency of contractions was less than three 
per 10 minutes each lasting for 45 seconds or the contractions pattern was 
dysfunctional. Oxytocin was administered not earlier than 4 hours after 
the last misoprostol dose, starting at 1 mU/minute and increased by           
1 mU/minute every 15 minute until adequate contractions persisted. 
Continuous fetal cardiotocography was used throughout the study. 
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Tachysystole was defined as at least six contractions per 10 
minutes during two consecutive 10-minute periods. Hypertonus was 
defined as a single uterine contraction lasting for 2 minutes or more. 
Hyperstimulation syndrome was defined as the presence of tachysystole 
or hypertonus associated with a nonreassuring FHR pattern (fetal 
tachycardia, late decelerations, severe variable decelerations or loss of 
FHR variability). All the episodes of hyperstimulation syndrome were 
included in the analysis regardless of the interval from the time of 
misoprostol administration to the occurrence of the abnormal FHR 
pattern. Recognised episodes of hyperstimulation were managed by 
stopping the oxytocin infusion, maternal repositioning, hydration and 
oxygen administration. In the sublingual group, the woman was advised to 
spit out the medication and wash her mouth, and for those in the vaginal 
group, the tablet was removed when possible. Labour induction was 
considered a failure if a woman did not enter the active phase of labour 
following six doses of misoprostol. The woman was then offered a 
caesarean section. 
Following outcome variables were measured. 
1. Number of women delivered vaginally within 24 hours of the first 
dose of misoprostol   
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2. Interval from the start of induction to vaginal delivery / induction 
delivery interval. 
3. Cesarean rates 
4. Number of misoprostol doses given 
5. Need for oxytocin augmentation 
6. Number of per vaginal examination 
7. Uterine tachysystole rates 
8. Uterine hypertonus rates 
9. Uterine hyperstimulation rates  
10. Other Maternal adverse effects 
11. Birth weight of baby 
12. Incidence of meconium-stained amniotic fluid 
13. Neonatal intensive care unit (NICU) admissions. 
14. 5 min APGAR score less than 7. 
The means between the groups were compared using an unpaired, 
two-tailed Student's t test. Categorical variables were analysed using chi-
square test.  P < 0.05 was considered statistically significant.  For discrete 
data, relative risk (RR) with 95% confidence intervals (CI) was used. 
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RESULTS AND ANALYSIS 
 
Table 1: Comparison of age [years] and parity 
 Group A[SLM] Group B [VM] 
Age [years] 25.07 ± 3.97 25.08 ± 3.70 
Parity 1.38 ± 0.72 1.32 ± 0.57 
Primigravida 42[70] 43[71] 
Multigravida 18[30] 17[29] 
  
Table 1 shows mean and standard deviation of age and parity in 
both groups. Primigravida and multigravida were shown in number 
[percentage]. There was no significant difference among the groups. 
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Table 2: Comparison of gestational age [weeks] 
 Group A[SLM] Group B [VM] P value 
Gestational age 
[weeks] 
39.92±1.92 39.32±1.59 0.849 
  
Table 2 shows mean and standard deviation of gestational age 
[weeks] in both groups. There was no significant difference among the 
groups. 
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Table 3: Comparison of bishop score 
 Group A[SLM] Group B [VM] P value 
Bishop score 4.03±0.81 4.05±0.59 1.00 
  
 
Table 3 shows mean and standard deviation of Bishop score in both 
groups. There was no significant difference among the groups. 
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Table 4: Comparison of indication for induction 
 Group A[SLM] Group B [VM] 
Post term [>41 weeks] 28[46.7] 25[41.7] 
Mild preeclampsia 11[18.3] 14[23.3] 
Gestational diabetes 
mellitus 4[6.7] 3[5] 
Prelabour rupture of 
membrame 17[28.3] 18[30] 
  
Table 4 shows number [percentage] of indication for induction in 
both groups. There was no significant difference among the groups. 
 
       
 
Chart 6 shows percentage of indication of induction. 
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Table 5: Comparison of total doses of misoprostol 
 Group A[SLM] Group B [VM] P value 
Total doses of 
misoprostol 1.85±1.02 2.3±1.2 <0.05 
  
Table 5 shows mean and standard deviation of total doses of 
misoprostol in both groups. Misoprostol used was significantly lower in 
sublingual route than vaginal route [p<0.05]. 
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Table 6: Comparison of number of vaginal delivery in 
< 24 hours of induction 
 Group A[SLM] Group B [VM] RR [CI 95%] 
Vaginal 
delivery 
< 24 hours 
52[86.7] 50[83.3] 1.04 [0.89 -1.20] 
  
Table 6 shows number [percentage] of vaginal delivery in <24 
hours in both groups. There was no significant difference among the 
groups. 
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Table 7: Comparison of number of pelvic examination 
 Group A[SLM] Group B [VM] P value 
Number of pelvic 
examination 5.75±2.05 8.22±2.04 P<0.05 
  
Table 7 shows mean and standard deviation of number of pelvic 
examination in both groups. Pelvic examination was significantly lower 
in sublingual route misoprostol than vaginal route of administration 
[p<0.05]. 
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Table 8: Comparison of oxytocin use 
 Group A[SLM] Group B [VM] RR [CI 95%] 
Oxytocin use 45[75] 47[78.3] 0.95 
[0.79 – 1.17] 
  
 
Table 8 shows number [percentage] of patients where oxytocin was 
used in both groups. There was no significant difference among the 
groups. 
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Table 9: Comparison of induction delivery interval [minutes] 
 Group A[SLM] Group B [VM] P value 
Induction 
delivery 
interval (min) 
650.98±250.83 779.7±269.97 P<0.05 
Induction 
vaginal 
delivery 
interval (min) 
597.42±186.47 720±195.47 P<0.005 
  
Table 9 shows mean and standard deviation of induction delivery 
interval including caesarean section [minutes] and induction vaginal 
delivery interval [minutes] in both groups. Induction delivery interval 
including caesarean section and induction vaginal delivery interval was 
significantly lower in sublingual route misoprostol than vaginal route of 
administration [p<0.05]. 
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Table 10: Comparison of mode of delivery 
 Group A[SLM] 
Group B 
[VM] RR [CI 95%] 
Spontaneous 
vaginal delivery 49[81.7] 45[75] 
1.09 [ 0.90 – 
1.32] 
Instrumental 
vaginal delivery 3[5] 5[8.3] 0.6 [ 0.15 – 2.40] 
Caesarean section 8[13.3] 10[16.7] 0.8 [ 0.34 -1.89] 
  
Table 10 shows number [percentage] of mode of delivery in both 
groups. There was no significant difference among the groups. 
 
        
Chart 12 shows percentage of mode of delivery 
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Table 11: Comparison of indication for caesarean section 
 Group A[SLM] 
Group B 
[VM] RR [CI 95%] 
Fetal distress 2[25] 3[30] 0.83 [ 0.18 – 3.84] 
Non progress of 
labour / arrest of 
labour 
4[50] 4[40] 1.25[0.45 – 3.49] 
Failed induction 2[25] 3[30] 0.83 [ 0.18 – 3.84] 
  
Table 11 shows number [percentage] of indication for caesarean 
section in both groups. There was no significant difference in fetal 
distress, non progress of labour / arrest of labour and failed induction 
among the groups. 
 
         
Chart 13 shows percentage of indication for caesarean section 
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Table 12: Comparison of maternal uterine complications  
 Group A[SLM] 
Group B 
[VM] RR [CI 95%] 
Tachysystole 6[10] 6[10] 1 [0.34 -2.93] 
Hypertonus 1[1.7] 1[1.7] 1 [0.06 – 15.62] 
Hyperstimulation 
syndrome 3[5]] 2[3.3] 1.5 [0.26 – 8.66] 
  
Table 12 shows number [percentage] of maternal uterine 
complication in both groups. There was no significant difference among 
the groups. Hyperstimulation syndrome had been treated by maternal left 
lateral position, O2 administration and infusing intravenous fluids. All the 
patients responded and all patients had delivered vaginally except one 
delivered by outlet forceps for failed maternal effort in vaginal group. 
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Table 13: Comparison of other maternal complications  
 Group A[SLM] Group B [VM] RR [CI 95%] 
Vomiting 2[3.3] 2[3.3] 1 [0.15 – 6.87] 
  
Table 13 shows number [percentage] of other maternal 
complications in both groups. There was no significant difference among 
the groups. 
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Table 14: Comparison of birth weight of baby [kilograms] 
 Group A[SLM] Group B [VM] P value 
Baby birth 
weight [kgs] 2.89±0.23 2.90±0.19 0.83 
 
Table 14 shows mean and standard deviation of baby birth weight 
[kilograms] in both groups. There was no significant difference among 
the groups. 
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Table 15: Comparison of fetal complications  
 Group A[SLM] Group B [VM] RR [CI 95%] 
Meconium 
passage 3[5] 3[5] 1 [0.21 – 4.76] 
Apgar score < 7 
at 5 minutes 2[3.3] 2[3.3] 1 [0.15 – 6.87] 
NICU admission 1[1.6] 2[3.3] 0.5 [ 0.05 – 5.37] 
  
Table 15 shows number [percentage] of fetal complication in both 
groups. There was no significant difference among the groups. 
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DISCUSSION 
 
In our study we had selected 180 patients as eligible candidates and 
120 patients were included in our study. So far as per pub med search 
machine sublingual misoprostol study was done on 160, 120, 140, 150 
and 170 patients.  
There was no difference in age, parity, gestational age, bishop 
score and indication of induction among the both groups in our study. 
The results had showed that 25μg of sublingual misoprostol 
administration resulted in significantly shorter induction to delivery 
interval [p <0.005], with a lower number of misoprostol doses required 
[p<0.01] and lesser number of pelvic examination [p<0.05] required as 
compared with those administered 25 μg of vaginal misoprostol.  
In Tang et al.5 study, the sublingual route has been shown to 
produce significantly higher serum peak concentration of misoprostol 
than either oral or vaginal administration. In addition, the area under the 
curve for plasma levels over 4 and 6 hours was significantly greater 
following sublingual administration than for either oral or vaginal 
administration. A recently published study evaluated the effects of 
misoprostol on uterine contractility following different routes of 
administration42. The sublingual application of misoprostol has, with 
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regard to effects on the myometrium, had rapid effect on uterine 
contractility as oral administration and the bioavailability was similar to 
that following vaginal administration. We had administered sublingual 
dosage every 4th hourly. These findings may explain the significant 
induction delivery interval with sublingual misoprostol in our study.  
A Bartusevicius et al4 had also observed same result in their study. 
They had used 50 μg of sublingual misoprostol in contrast to 25 μg in our 
study. Our study had showed that 25 μg administered sublingual was 
equivalent to 25 μg administered vaginally in their effect like  shortening 
the  induction delivery time and also the number of misoprostol tablets 
used for induction.it may decrease the cost of management.  Feitossa        
et al.43 had observed Vaginal delivery rates were 57% in the sublingual 
group and 69% in the vaginal group (RR, 0.8; 95% CI, 0.6–1.1). There 
were 11 cases of fetal distress in the sublingual group and 4 cases in the 
vaginal group (RR, 2.7; 95% CI, 0.9–8.2). They had used 25 μg of 
sublingual misoprostol every 6 hourly. Though they had observed 
significant difference in value between the groups, percentage of vaginal 
delivery was very small compared to our study [57% & 69% Vs 81.7% & 
75%]. It may be due to their higher dosing interval [6 hours Vs 4 hours] 
than our study. 
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Tang et al.5 on studying pharmacokinetics of misoprostol in 
different route of administration had found that at the end of 6 h, the 
serum levels of MPA in the vaginal groups were higher than those of the 
sublingual and oral routes. Sublingual dosage interval should be less than 
this interval to get significant plasma levels. Lower vaginal delivery 
percentage in Feitossa et al.43 study might be due to their higher dosage 
interval [6 hours Vs 4 hours].  So in our study we used 4 hours as repeat 
dosing interval. 
Induction delivery interval measurement would have lot of bias 
because for cesarean section a team of doctors and paramedical staffs 
were required. There might be difference in duration for shifting the 
patient to operation theatre and administering anaesthesia. We had 
included that parameter in our study because there was no significant 
difference in number of caesarean section rate and indication for 
caesarean section among the groups. 
Our study had showed a significant reduction in number of pelvic 
examination before delivery. Patient would be comfortable when number 
of pelvic examination was reduced. We had not taken satisfaction 
parameter in our study as it was beyond our scope. Nasser et al8 had 
studied on patient satisfaction criteria and they had concluded that 
sublingual misoprostol was satisfactory route of administration than 
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vaginal route. This route of administration may reduce the chance of 
infection particularly in PROM cases because of less number of vaginal 
examinations required. On considering these facts and our observation on 
significant decrease in number of pelvic examination sublingual route 
may be a satisfactory route of administering misoprostol. 
In our study there was no significant difference in mode of 
delivery. There was no significant difference in indication for   caesarean 
delivery. It was similar to study conducted by Bartusevicius et al.4 but 
they had used 50 μg of sublingual misoprostol. It showed that reduction 
of sublingual dosage from 50 μg to 25 μg had retained its effect on uterus 
without altering the mode of delivery and number of women delivered 
vaginally within 24 hours. 
Different routes of misoprostol administration for labour induction 
necessitate carefully balancing the benefit (shorter time until delivery) against the 
risk (uterine hyperstimulation, adverse neonatal and maternal outcomes). Incidence 
of tachysystole {RR [CI 95%]-1 [0.34 -2.93]}, hypertonus {RR [CI 95%] -1 [0.06 – 
15.62]} and hyperstimulation syndrome {RR [CI 95%]-1.5 [0.26 – 8.66]} was 
not significant in our study. In a recent study4 where they had used 50 μg 
of sublingual misoprostol had noted three fold higher incidence of 
tachysystole in the sublingual than in the vaginal group. There were no 
significant differences between the two groups with respect to the number 
 45 
of women experiencing hyperstimulation syndrome, or with regard to the 
mode of delivery or neonatal outcome, bearing in mind that their sample 
size was not powered to evaluate the parameters for safety. In our study 
we had observed no significant value for tachysystole with 25 μg of 
sublingual misoprostol, still we cannot conclude on adverse effect due to 
our sample size. Recent study had concluded that avoidance of a direct 
effect on the cervix did not reduce the risk of excessive uterine activity, 
as noted before but from our study reducing dosage can reduce this risk 
without compromising on our prime aim. 
The neonatal outcomes were similar in both the trial groups. 
Comparable neonatal outcomes were noted in another study after 50 μg of 
misoprostol administered sublingually or vaginally.  There was no 
significant difference in birth weight of baby [p>0.05] among the study 
groups. In term of other maternal complication, in our study patient had 
developed vomiting in two patients in each group.  Misoprostol tablet as 
such had unpleasant taste.  From our study, we found that vomiting can 
occur irrespective of route of administration. It might be due to systemic 
action of absorbed misoprostol. It needs large sample study to get 
inference for this complication.  In view of the limited sample size of our 
study, we cannot reach definitive conclusions about the safety of 
sublingual misoprostol in this setting. 
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Sublingual dosing for labour induction is attractive because of ease 
of administration, less frequent need for vaginal examination, greater 
freedom of position and the possibility of its use despite vaginal bleeding 
or ruptured membranes. Cost of management was also low when 
comparing to other modes of induction. Even though this was not 
assessed in the present study, we assume higher patient acceptance of 
sublingual route, which was observed with oral when compared with 
vaginal administration. 
  
 
 
 
 
 
 
Summary  
 
 
 
 
 
 
 
 
 
 
 47 
 
SUMMARY 
 
120 patients those for labour induction at term among whom 60 
patients were administered 25 μg sublingual misoprostol every 4th hourly 
for maximum of 6 doses and remaining 60 patients were administered           
25 μg vaginal misoprostol every 4th hourly for maximum of 6 doses were 
compared for efficacy and safety. Following outcome variables were measured 
and means between the groups were compared using an unpaired, two-
tailed Student's t test. Categorical variables were analysed using chi-
square test.  P < 0.05 was considered statistically significant. For discrete 
data, relative risk (RR) with 95% confidence intervals (CI) was used. 
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CRITERIA 
SUBLINGUAL 
MISOPROSTOL 
n = 60 
VAGINAL 
MISOPROSTOL 
n = 60 
RELATIVE 
RISK[95% CI] 
OR P Value 
Vaginal delivery <24 
hours 
52[86.7] 50[83.3] 1.04 [0.89 -1.20] 
Total doses of 
misoprostol 
1.85±1.02 
 
2.3±1.2 
 
P<0.05 
Induction delivery 
interval (min) 
650.98±250.83 
 
779.7±269.97 
 
P<0.05 
Induction vaginal 
delivery interval (min) 
597.42±186.47 
 
720±195.47 
 
P<0.005 
Number of pelvic 
examination 
5.75±2.05 
 
8.22±2.04 
 
P<0.05 
Mode of delivery    
Spontaneous vaginal 
delivery 
49[81.7] 45[75] 1.09 [ 0.90 – 1.32] 
Instrumental vaginal 
delivery 
3[5] 5[8.3] 0.6 [ 0.15 – 2.40] 
Caesarean section 8[13.3] 10[16.7] 0.8 [ 0.34 -1.89] 
Indication for 
caesarean delivery 
   
Fetal distress 2[25] 3[30] 0.83 [ 0.18 – 3.84] 
Non progress of labour 4[50] 4[40] 1.25[0.45 – 3.49] 
Failed induction 2[25] 3[30] 0.83 [ 0.18 – 3.84] 
Oxytocin use 45[75] 47[78.3] 0.95 [0.79 – 1.17] 
Tachysystole 6[10] 6[10] 1 [0.34 -2.93] 
Hypertonus 1[1.7] 1[1.7] 1 [0.06 – 15.62] 
Hyperstimulation 
syndrome 
3[5]] 2[3.3] 1.5 [0.26 – 8.66] 
Birth weight (kgs) 2.89±0.23 2.90±0.19 0.83 
Apgar score < 7 at 5 
minutes 
2[3.3] 2[3.3] 1 [0.21 – 4.76] 
Meconium passage 3[5] 3[5] 1 [0.15 – 6.87] 
NICU admission 1[1.6] 2[3.3] 0.5 [ 0.05 – 5.37] 
Maternal complication    
vomiting 2[3.3] 2[3.3] 1 [0.15 – 6.87] 
Values as mean±SD, numbers[percentage] 
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Misoprostol used was significantly lower in sublingual route than vaginal 
route [p<0.05]. 
· Pelvic examination was significantly lower in sublingual route 
misoprostol than vaginal route of administration [p<0.05], thereby 
inconvenience caused by pelvic examination was less in sublingual 
route. 
· Induction delivery interval including caesarean section and 
induction vaginal delivery interval was significantly lower in 
sublingual route misoprostol than vaginal route of administration 
[p<0.05]. 
· There was no significant difference among the groups in vaginal 
delivery in less than 24 hours. 
· There was no significant difference among the groups in number 
[percentage] of patients where oxytocin was used in both groups 
· There was no significant difference among the groups in number 
[percentage] of mode of delivery. 
· There was no significant difference in fetal distress, non progress 
of labour / arrest of labour and failed induction among the groups. 
· There was no significant difference among the groups in number 
[percentage] of maternal uterine complication. 
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· Two patient in each group developed vomiting. 
· There was no significant difference among the groups in terms of 
meconium passage, Apgar score < 7 at 5 minutes and NICU 
admission. 
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CONCLUSION 
 
we conclude that 25 μg of sublingual misoprostol administered 
every 4th hourly for maximum of 6 doses was more effective for induction 
in full term pregnancy than 25 μg of vaginal misoprostol administered 
every 4th hourly for maximum of 6 doses in terms of shortened induction 
delivery interval, less number of misoprostol tablets required and less 
number of pelvic examination required. It neither alter vaginal delivery 
rate and caesarean section rate nor produce significant complications like 
hypertonus, tachysystole and hyperstimulation syndrome than vaginal 
misoprostol route of administration. We believe further studies on safety 
with larger numbers of women need to be conducted before we advocate 
sublingual misoprostol as routine labour induction agent. 
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Proforma  
 
 
 
 
 
 
 
 
 
 
 PROFORMA 
 
NAME:   AGE:    IP NO: 
DOA:    BOOKING STATUS: IMMUNISATION: 
OBSTETRIC CODE: LMP:    EDD: 
MENSTURAL HISTORY: 
 
PREVIOUS PREGNANCY OUTCOME: 
PREGNANCY ASSOCIATED COMPLICATION: 
· MATERNAL   : 
· FETAL  : 
MEDICAL DISEASE: 
 
EXAMINATION 
PALLOR/JAUNDICE/PEDAL EDEMA/FEBRILE 
HEIGHT:  WEIGHT :  BMI : 
PULSE   :  BP      :  RR   :    TEMPERATURE: 
CVS        : 
RS          : 
P/A        : 
Ø Uterus 
Ø Acting / not acting 
 Ø Head Engagement 
Ø FH 
Ø Liquor 
 
P/V: 
Ø Cervix       Bishop Score: 
o Effacement 
o Dilatation 
o Position 
o Consistency 
Ø Membrane 
Ø Vertex station 
Ø Pelvis 
Ø Liquor draining: Y/N  Colour of liquor: 
 INVESTIGATION: 
· Hb 
· Urine routine 
· Blood grouping& typing 
· USG   GA:  AFI:   
· CTG 
 INDICATION FOR INDUCTION:  
ROUTE OF ADMINISTRATION  :   SLM/VM 
TIME AT THE START OF INDUCTION: 
Number of misoprostol 
tablets 
1 2 3 4 5 6 
Time of administation       
 
OXYTOCIN USE: Y/N 
MODE OF DELIVERY: 
    SVD  IVD  CS 
         Indication: 
TIME OF DELIVERY:   
INDUCTION DELIVERY INTERVAL: 
NUMBER OF PELVIC EXAMINATION: 
 
SIDE EFFECTS: 
Ø MATERNAL: 
o Uterine tachysystole 
o Hypertonus 
o Hyper stimulation syndrome 
o Systemic 
 BABY: 
· Sex 
· Birth weight 
· Apgar score at 5 mins 
· Meconium stained liquor 
· NICU admission: Y/N  Reason for admission: 
COMPLICATION: 
Ø Intrapartum 
Ø Post partum 
Ø Neonatal 
 
Date: 
S. No : 
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1. Lakshmi 28 2588 P 1 41 3 PD VM 6 13 N N N N CS 0 1564 FI N 3.2 N N 9 
2. Usha 20 8330 P 1 38 4 MPE VM 2 7 Y N N N SVD 944 944 N N 2.8 N N 9 
3. Valarmathi 22 9502 P 1 38 3 PROM VM 2 8 Y N N N SVD 670 670 N N 2.7 N N 9 
4. Amudham 18 10310 P 1 41 3 PD VM 4 10 Y N N N SVD 1060 1060 N N 3 MCL N 9 
5. Muthulaxmi 23 10354 P 1 40 5 PROM SLM 1 3 Y N N N SVD 324 324 N N 2.9 N N 9 
6. Manjula 24 10987 P 1 42 3 PD SLM 3 9 Y N N N SVD 844 844 N N 2.7 N N 9 
7. Amutha 27 11225 P 1 37 5 PROM SLM 1 4 N Y N N SVD 340 340 N N 2.8 N N 8 
8. Pappathi 27 12035 G2P1L1 2 38 3 PROM SLM 3 10 Y N N N CS 0 944 NPL N 2.8 N N 8 
9. Praveena 23 12458 P 1 41 4 PD SLM 2 6 Y N N N SVD 610 610 N N 2.7 N N 8 
10. Angurani 26 12546 G3P1L1A1 3 41 3 PD SLM 2 7 Y N N N SVD 688 688 N N 2.7 N N 9 
11. Fairose 34 12784 G2P1L1 1 43 3 PD SLM 3 8 N N N N SVD 790 790 N N 2.6 N N 8 
12. Lakna 19 13541 P 1 38 4 MPE VM 2 8 Y N N N IVD 769 769 N N 3.2 N N 9 
13. Selvarani 28 13542 P 1 40 4 GDM SLM 2 7 Y N N N CS 0 866 FD N 2.7 N N 9 
14. Lalitha 25 13547 P 1 38 5 PROM SLM 1 4 Y N N N SVD 510 510 N N 2.8 N N 9 
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15. Rathnammal 26 14436 P 1 38 4 PROM VM 2 6 N N N N SVD 692 692 N N 2.6 N N 9 
16. Govindamma 29 14578 G2P1L1 2 38 5 MPE SLM 1 4 Y N N N SVD 415 415 N N 2.9 N N 8 
17. Rejula 20 15040 P 1 41 4 PD SLM 1 4 Y Y N Y SVD 364 364 N N 2.8 N N 9 
18. Parimala 28 15069 G2P1L1 2 39 5 MPE VM 1 8 Y N N N SVD 454 454 N N 2.8 N N 9 
19. Chellathaye 24 15088 P 1 41 4 PD VM 2 8 Y N N N SVD 644 644 N N 2.8 N N 9 
20. Uma 26 15320 P 1 41 5 PROM SLM 1 3 N Y N N SVD 810 810 N N 3.2 N N 9 
21. Sathya  21 15410 P 1 37 5 MPE SLM 2 7 Y N N N SVD 744 744 N N 3 N N 9 
22. Padma 22 15478 P 1 41 4 PD SLM 1 4 Y N N N SVD 310 310 N N 2.6 N N 9 
23. Nirmala 29 15512 P 1 41 4 PD VM 2 7 Y N N N SVD 646 646 N N 2.9 N N 9 
24. Nirupa 31 15642 G3P1L1A1 3 41 4 PD VM 2 7 Y N N N CS 0 788 FD N 3 N Y 6 
25. Thangam 29 15776 P 1 42 4 PD VM 2 9 Y N N N SVD 890 890 N N 2.9 N N 9 
26. Valli 29 16372 G2P1L1 2 38 4 MPE VM 2 9 Y Y N Y SVD 800 800 N N 2.8 N N 8 
27. Palaniammal 19 16420 P 1 40 4 PROM SLM 1 4 Y N N N SVD 348 348 N N 2.6 N N 9 
28. Sumathi 27 16587 P 1 41 4 PD SLM 2 8 Y N N N SVD 710 710 N N 3.1 N N 9 
29. Thangathai 30 16763 P 1 41 4 PD VM 2 7 Y N N N SVD 988 988 N N 2.7 N N 9 
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30. Aruldevi 22 17940 P 1 41 4 PD VM 3 9 Y N N N SVD 890 890 N N 3 N N 8 
31. Akila 24 18185 P 1 38 5 MPE VM 1 9 Y N N N SVD 322 322 N N 2.8 N N 9 
32. Maheshwari 18 18742 P 1 42 5 PD SLM 1 4 Y N N N SVD 290 290 N N 2.8 N N 9 
33. Sathya 24 18927 P 1 39 4 PROM VM 2 7 Y N N N SVD 688 688 N N 3.1 N N 9 
34. Parasakthi 25 20365 G2P1L1 2 37 4 MPE SLM 1 4 Y N N N SVD 510 510 N N 3 N N 9 
35. Rajeshwari 29 20376 G2P1L1 2 41 4 PD VM 2 7 Y N N N SVD 906 906 N N 2.8 N N 9 
36. Vanitha 29 20546 G2P1L1 2 37 4 PROM VM 3 10 Y Y N N SVD 910 910 N N 2.8 MSL N 8 
37. Rathna 26 21032 P 1 42 4 PD SLM 1 3 Y N N N SVD 432 432 N N 3.4 N N 9 
38. Suguna 28 21265 G2P1L1 2 38 4 GDM VM 1 5 N N N N SVD 344 344 N N 2.8 N N 9 
39. Kalaimahal 28 21302 P 1 38 5 PROM VM 3 11 N N N N SVD 845 845 N N 2.9 N N 9 
40. Rajamani 23 21356 P 1 42 4 PD SLM 3 9 Y Y N Y SVD 986 986 N N 2.9 MSL N 8 
41. Prathiba 30 21382 G2P1L1 2 42 5 PD SLM 2 6 Y N N N IVD 740 740 N N 2.8 N N 8 
42. Thangam 19 21400 P 1 37 3 PROM SLM 2 6 Y N N N CS 0 840 NPL N 2.6 N N 8 
43. Raja rajeshwari 24 21456 G4P2L2A1 4 41 5 PD SLM 1 4 N Y N N SVD 458 458 N N 2.8 N N 9 
44. Gracy 29 21458 P 1 40 4 GDM SLM 2 7 Y N N N SVD 710 710 N N 2.8 N N 9 
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45. Vijayalakshmi 24 21547 P 1 38 4 MPE SLM 2 4 Y N N N SVD 720 720 N N 2.5 N N 9 
46. Maha 23 21636 P 1 39 4 MPE VM 1 5 N N N N SVD 700 700 N N 2.9 N N 9 
47. Sujitha 21 22214 P 1 39 3 PROM SLM 1 3 Y N N N IVD 554 554 N N 3.4 N N 8 
48. Juliet regina 23 22314 P 1 43 3 PD SLM 3 9 Y N N N CS 0 967 NPL N 2.6 N N 8 
49. Suseela 21 22356 P 1 39 3 PROM SLM 2 7 Y N N N SVD 654 654 N N 2.8 N N 9 
50. Radhika 23 22733 P 1 41 4 PD VM 2 8 Y N N N SVD 688 688 N N 3 N N 8 
51. Anisha begum 26 23548 P 1 38 4 PROM VM 2 9 Y N N N SVD 723 723 N N 3.2 N N 9 
52. Kalavathy 20 23564 P 1 42 2 PD SLM 3 9 Y N N N SVD 824 824 N VOM 3 N N 9 
53. Suganya 25 24112 G2P1L1 2 41 4 PD VM 2 7 Y N N N SVD 755 755 N N 3.2 N N 9 
54. Senmalar 28 24510 P 1 42 3 PD SLM 6 7 N N N N CS 0 1466 FI N 2.8 N N 8 
55. Parameshwari 22 24781 P 1 38 3 MPE VM 3 9 Y N N N SVD 896 896 N N 2.6 N N 9 
56. Saradha 20 24884 P 1 41 4 PD VM 3 10 Y N N N SVD 1056 1056 N VOM 2.6 N N 9 
57. Jashitha 18 25108 P 1 42 4 PD SLM 2 8 Y N N N CS 0 780 NPL N 3 N N 7 
58. Rathinam 28 25210 P 1 39 5 PROM SLM 2 6 N N N N SVD 823 823 N N 2.6 N N 9 
59. Meenakshi 28 25462 P 1 42 4 PD SLM 3 9 N N N N SVD 788 788 N N 3.1 N N 8 
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60. Revathi 26 25467 P 1 37 3 GDM SLM 2 8 Y N N N SVD 584 584 N N 2.9 N N 9 
61. Mallika 23 25472 P 1 41 5 PD SLM 2 6 Y N N N SVD 463 463 N N 2.7 N N 9 
62. Kalyani 22 25478 P 1 37 2 MPE SLM 2 7 Y N N N SVD 630 630 N N 2.8 N N 8 
63. Vinisha 21 25484 G2P1L1 2 38 4 PROM VM 1 5 Y N N N SVD 566 566 N N 2.7 N N 9 
64. Ponni 28 25496 P 1 41 4 PD VM 2 10 Y N N N SVD 802 802 N N 2.8 N N 9 
65. Akilandam 26 25564 G2P1L1 2 43 4 PD SLM 2 8 Y N Y Y SVD 810 810 N N 3 N N 8 
66. Kamathchi 26 25616 P 1 38 4 MPE VM 3 9 Y N N N IVD 900 900 N N 3.2 N N 8 
67. Anifa 35 25674 G2P1L1 2 40 5 GDM SLM 2 7 Y N N N SVD 682 682 N N 3 N N 9 
68. Karaimathi 22 25689 G3P2L2 3 38 3 MPE SLM 2 6 N N N N SVD 732 732 N N 2.8 N N 8 
69. Sivakami 31 25698 G2P1L1 2 40 4 PROM SLM 1 3 N N N N SVD 768 768 N N 3 N N 9 
70. Vinitha 23 25714 P 1 37 5 MPE SLM 2 8 Y N N N SVD 684 684 N N 2.8 N N 9 
71. Annie mathew 31 25848 G2P1L1 2 41 5 PD VM 2 8 Y N N N SVD 890 890 N N 2.6 N N 9 
72. Mayil 22 26651 P 1 42 5 PD SLM 2 7 Y N N N SVD 744 744 N N 3.2 N N 8 
73. Aiyyamal 25 27458 G2P1L1 2 42 4 PD SLM 1 3 Y Y N N SVD 324 324 N N 3 MSL N 9 
74. Senbagam 24 27951 P 1 38 3 PROM VM 6 13 N N N N CS 0 1500 FI N 3.4 N N 9 
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75. Priya 22 31589 P 1 38 5 GDM VM 2 8 Y N N N SVD 788 788 N N 2.8 N N 9 
76. Vijayarani 35 31699 G2P1L1 2 41 3 PD VM 2 8 Y N N N SVD 932 932 N N 2.9 N N 9 
77. Manjula 28 32293 P 1 40 4 PROM VM 6 13 N N N N CS 0 1490 FI N 3 N N 9 
78. Shahira 30 32312 P 1 41 4 PD SLM 2 6 Y N N N SVD 621 621 N N 3.2 N N 9 
79. Shantha kumari 32 32460 G3P1L1A1 3 41 4 PD SLM 1 4 Y N N N SVD 310 310 N N 2.8 N N 9 
80. Elaiyammal 28 32541 P 1 37 4 MPE SLM 2 8 Y N N N SVD 742 742 N N 3.4 N N 9 
81. Vijaya 21 32546 P 1 41 4 PD VM 3 9 Y Y N N SVD 910 910 N N 3 N N 9 
82. Thennai valli 35 32550 G2P1L1 2 40 4 PROM SLM 1 4 Y N N N CS 0 566 FD N 3.4 N Y 6 
83. Sathya priya 24 32552 P 1 41 4 PD SLM 2 6 Y N N N SVD 942 942 N N 2.9 N N 9 
84. Karpagam 25 32560 P 1 41 4 PD SLM 2 6 Y N N N SVD 654 654 N N 3.2 N N 9 
85. Savithri 27 32564 P 1 37 5 MPE SLM 1 4 N N N N SVD 354 354 N N 2.9 N N 9 
86. Cheela kaur 22 32566 P 1 42 4 PD SLM 6 6 Y N N N CS 0 1564 FI N 2.7 N N 9 
87. Banumathy 26 32568 G2P1L1 2 38 5 PROM SLM 1 3 N N N N SVD 486 486 N N 2.9 N N 8 
88. Arokiya  24 34561 P 1 39 4 PROM VM 2 8 Y N N N SVD 890 890 N N 2.8 N N 8 
89. Yashmin banu 22 35447 P 1 38 4 PROM SLM 2 4 N N N N SVD 400 400 N VOM 3 N N 8 
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90. Logeshwari 25 35624 P 1 37 4 MPE SLM 2 8 Y N N N SVD 748 748 N N 2.8 N N 9 
91. Vasantha rubini 20 36985 P 1 41 4 PD SLM 2 7 Y N N N SVD 684 684 N N 3.1 N N 8 
92. Rosemary 26 37321 P 1 41 5 PD VM 2 8 Y N N N SVD 806 806 N N 2.8 N N 8 
93. Veerayee 21 38100 P 1 39 4 PROM VM 3 11 Y N N N CS 0 832 NPL N 2.8 N N 9 
94. Mala 28 38971 G3P2L2 3 40 4 PROM SLM 1 5 Y N N N SVD 422 422 N N 3.3 MSL N 9 
95. Sarasu 28 39452 G2P1L1 2 37 4 MPE VM 1 5 Y N N N SVD 466 466 N N 2.7 N N 9 
96. Vasuki 20 41256 P 1 40 5 PROM SLM 1 3 N N N N SVD 522 522 N N 2.5 N N 8 
97. Neelavathi 31 41470 G3P2P2 3 37 5 PROM VM 1 4 N N N N IVD 639 639 N N 2.9 N N 9 
98. Kasambu 26 42071 G2P1L0 2 38 5 PROM VM 2 8 Y N N N CS 0 844 NPL N 3.4 N N 9 
99. Lakshmi 25 44163 G2P1L1 2 41 5 PD VM 1 6 Y N N N IVD 340 340 N N 2.8 N N 9 
100. Sultana 24 45682 P 1 38 3 PROM VM 2 9 Y Y N N SVD 688 688 N N 3.1 N N 8 
101. Devi chitra 26 45784 P 1 40 4 PROM SLM 1 3 N N N N SVD 650 650 N N 2.6 N N 9 
102. Hairunisha 31 46058 P 1 38 4 PROM VM 2 8 Y N N N SVD 543 543 N VOM 2.8 N N 9 
103. Kokila 26 49630 P 1 38 5 GDM VM 2 9 N N N N CS 0 644 FD N 2.7 MSL Y 7 
104. Sellarani 24 49942 P 1 41 4 PD VM 3 8 Y Y N N SVD 784 784 N N 2.9 N N 9 
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105. Kalaiselvi 26 50442 G3P2L1 3 37 4 MPE VM 1 5 N N N N SVD 324 324 N N 3 N N 9 
106. Pappathi 24 51548 P 1 38 4 MPE VM 2 9 Y N N N SVD 568 568 N N 3 N N 9 
107. Poomani 21 51872 P 1 41 3 PD VM 6 13 N N N N CS 0 1540 FI N 2.8 N N 9 
108. Thilagavathy 22 52004 P 1 38 4 PROM VM 2 9 Y N N N SVD 655 655 N N 3.2 N N 9 
109. Lalitha 20 53134 P 1 41 4 PD VM 3 7 N N N N SVD 866 866 N N 2.8 N N 9 
110. Rajeshwari 19 53868 P 1 38 4 PROM VM 1 5 Y N N N SVD 432 432 N N 3.1 N N 8 
111. Vishi begum 24 54215 P 1 38 4 MPE VM 2 9 N N N N SVD 810 810 N N 2.7 N N 9 
112. Rahmath 25 54551 P 1 41 3 PD VM 2 9 Y Y N Y IVD 644 644 N N 2.8 N N 9 
113. Arokiaya mary 23 54621 P 1 38 5 MPE VM 3 9 Y N N N CS 0 844 NPL N 2.8 N N 9 
114. Noorjahan 29 54626 P 1 41 4 PD VM 2 8 Y N N N CS 0 730 NPL N 2.8 N N 8 
115. Banupriya 23 55410 G2P1L1 2 42 4 PD VM 2 10 Y N N N SVD 744 744 N N 2.6 N N 9 
116. Tamilselvi 28 57376 P 1 41 4 PD VM 2 8 Y N Y N SVD 453 453 N N 3.1 N N 9 
117. Vellamal 22 57986 P 1 38 5 PROM VM 1 5 Y N N N SVD 420 420 N N 2.9 N N 9 
118. Sangeetha 27 59320 G3P2L1 3 38 3 PD SLM 1 3 Y N N N SVD 490 490 N N 2.8 N N 9 
119. Annama 21 65842 P 1 37 4 MPE VM 2 7 Y N N N SVD 866 866 N N 3 N N 9 
120. Akila  26 65868 G2P1L1 2 38 4 MPE SLM 1 5 N N N N SVD 284 284 N N 2.8 N N 9 
 ABBREVIATIONS 
IP number Inpatient number 
Gn  Pn  Ln An   Gravida, para, live birth, abortion. n – Number 
PD Post dated 
MPE Mild pre eclampsia 
PROM Prelabor rupture of membrance 
GDM Gestational diabetic mellitus 
SLM Sublingual misoprostol 
VM Vaginal misoprostol 
Y,N Yes, No 
SVD Spontaneous vaginal delivery 
IVD Instrumental vaginal delivery 
CS Caesarean section 
NPL Non progress of labour 
FD Fetal distress 
FI Failed Induction 
 VOM Vomiting 
MSL Meconium stained liquor 
MINS Minutes 
KGS Kilograms 
YRS Years 
RR Relative risk 
CI Confidence interval 
NICU Neonatal intensive care unit 
µg Microgram 
CTG Cardiotocography 
IUD Intrauterine Fetal Death 
FHR Fetal Heart Rate 
GA Gestational Age 
BP Blood Pressure 
 
